What is Theriva™ Biologics stock symbol? Our stock is traded on the NYSE American under the symbol TOVX. Can I buy stock directly from Theriva Biologics? No, you will need to contact a licensed stock broker or use an online trading account. Where is Theriva Biologics located? 9605 Medical Center Dr.Suite 270Rockville, MD 20850 When […]
Governance Documents Code of Conduct Code of Ethics for Financial Management Audit Committee Charter Compensation Committee Charter Nominations Committee Charter Other Links View Our Leadership Team View Our Board of Directors Committee Composition Audit Committee Compensation Committee Nominations Committee Jeffrey Wolf, JD Chair Member Member Jeffrey J. Kraws Member Chair Member John Monahan, Ph.D. Member
Corporate Governance Read More »
Theriva™ Biologics (NYSE AMERICAN: TOVX) Analyst Coverage Firm Analyst A.G.P. / Alliance Global Partners James Molloy Maxim Group Jason McCarthy, Ph.D
ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D
ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share
Synthetic Biologics Announces Reverse Stock Split Read More »
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- – Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose
-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind
Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and extension into oncology ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the strengthening
– VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential to improve systemic delivery and extend therapeutic efficacy through a multi-dosing strategy- – Data to be featured in an oral presentation on Monday, May 16 at 5:15 p.m. ET- ROCKVILLE, Md., May 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc.
